Taltz ® (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Taltz Summary of Product Characteristics (SmPC)

Taltz® (ixekizumab): Addition of Methotrexate in Patients with Plaque Psoriasis

The safety and efficacy of combination therapy with ixekizumab and methotrexate in patients with plaque psoriasis have not been evaluated.

Detailed Information

  • During the ixekizumab pivotal UNCOVER clinical trials, treatment with concomitant systemic psoriasis therapies, including methotrexate, was not permitted. Patients were excluded if they had received methotrexate within 4 weeks of the baseline visit.1

  • Only limited use of specified topical therapies (eg, class 6 [mild] or class 7 [least potent] topical corticosteroids) was permitted as defined in the protocols. The rationales for excluding concomitant medications were the potential negative safety impact on patients enrolled in the study and the potential to confound the results of the study.1

Therapeutic Indications

Plaque psoriasis

Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.2


1. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345-356. http://dx.doi.org/10.1056/NEJMoa1512711

2. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: February 26, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request